WSI Swings to Operating Loss in Q1 2026 Consolidated, Standalone OP Maintains

Consolidated operating loss of KRW 0.17bn (vs operating profit of KRW 3.92bn in Q1 2025), consolidated net loss of KRW 0.06bn (controlling interest net profit of KRW 0.10bn)
Standalone operating profit of KRW 0.45bn (vs KRW 2.42bn), standalone net profit of KRW 0.34bn (vs KRW 0.13bn)
Consolidated revenue KRW 11.95bn (vs KRW 12.82bn, -6.8%)
Increase in SG&A due to allowance for bad debts of KRW 2.2bn and inventory valuation loss of KRW 0.3bn
Subsidiary IntroBioPharma: revenue KRW 3.75bn, net income KRW 0.33bn
Subsidiary EasyMediBot: net loss KRW 0.36bn, parent guarantee of KRW 2.11bn
Redeemable convertible preferred stock liability KRW 1.06bn, derivative liabilities KRW 1.38bn
Borrowings KRW 10.75bn, cash KRW 6.97bn, net debt KRW 4.85bn (gearing ratio 7.2%)
Dividend: no dividend plan for the period